Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ceribell, Inc.CBLL · Entity 4994 | Director | June 02, 2026 | June 04, 2026 |
| Lucira Health, Inc.LHDX · Entity 115613 | Director | June 01, 2022 | June 03, 2022 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Director | June 05, 2025 | June 10, 2025 |
| Silk Road Medical IncSILK · Entity 87417 | Director · President and CEO | March 02, 2021 | September 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ceribell, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,054 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,838 · Balance 33,054 F1: Represents restricted stock units ("RSUs"). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs").
Lucira Health, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-05-31 | Direct | 59,459 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 59,459 · Balance 59,459 F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting.
Sight Sciences, Inc.
Report date June 05, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,352 |
Reported balance
After 2025-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 30,952 · Balance 175,352 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $130,000 divided by the closing price of the Common Stock on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs, which are subject to vesting as reported herein, and (iii) 100,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $130,000 divided by the closing price of the Common Stock on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.
F2: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs, which are subject to vesting as reported herein, and (iii) 100,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025.
Silk Road Medical Inc
Report date March 02, 2021 · Filed September 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 267,988 |
Reported balance
After 2021-03-02 transaction · row 1
1 source rowRow 1 · 2021-03-02 · Sale · Disposed 1,651 · Balance 267,988 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F2: This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on September 11, 2020, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F2: This transaction was executed in multiple trades at price ranging from $56.55 to $56.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2020 Filed May 13, 2020 18:04 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 858 | $1.38 | $1,184.04 |
DisclosureSEC source: 0001593968-20-001158 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 2,744 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · derivative · entry 7 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,846 Underlying: Common Stock · 2,744 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 2,744 | $35.00 | $96,040.00 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · nonDerivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,921 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 2,744 | $1.38 | $3,786.72 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · nonDerivative · entry 3 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 17,300 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · derivative · entry 6 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,590 Underlying: Common Stock · 17,300 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 17,300 | $35.02 | $605,807.94 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,921 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F2 · price: This transaction was executed in multiple trades at price ranging from $35.00 to $35.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 18:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 17,300 | $1.38 | $23,874.00 |
DisclosureSEC source: 0001593968-20-001006 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 18:26 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 91,950 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001593968-20-000923 · primary_01.xml · derivative · entry 3 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,950 Underlying: Common Stock · 91,950 shares Expires 2030-03-27 F3 · derivative.exercise_date: One forty-eighth of the shares subject to the option shall vest on April 1, 2020 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 18:26 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 13,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000923 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,921 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the RSUs vest on March 1, 2021 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 17:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 20,044 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-20-000767 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,890 Underlying: Common Stock · 20,044 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 17:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 20,044 | $37.36 | $748,942.06 |
DisclosureSEC source: 0001593968-20-000767 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F2 · price: This transaction was executed in multiple trades at price ranging from $36.51 to $38.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 17:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 20,044 | $1.38 | $27,660.72 |
DisclosureSEC source: 0001593968-20-000767 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 20,044 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-20-000441 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,934 Underlying: Common Stock · 20,044 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 20,044 | $47.43 | $950,646.83 |
DisclosureSEC source: 0001593968-20-000441 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F2 · price: This transaction was executed in multiple trades at price ranging from $46.92 to $47.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:58 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 20,044 | $1.38 | $27,660.72 |
DisclosureSEC source: 0001593968-20-000441 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 20:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 20,044 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-20-000150 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,978 Underlying: Common Stock · 20,044 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 20:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 20,044 | $40.53 | $812,341.23 |
DisclosureSEC source: 0001593968-20-000150 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F2 · price: This transaction was executed in multiple trades at price ranging from $40.14 to $40.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 20:47 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 20,044 | $1.38 | $27,660.72 |
DisclosureSEC source: 0001593968-20-000150 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 18,397 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · derivative · entry 7 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,022 Underlying: Common Stock · 18,397 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 18,397 | $35.00 | $643,895.00 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · nonDerivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 18,397 | $1.38 | $25,387.86 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · nonDerivative · entry 3 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 1,647 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · derivative · entry 6 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,419 Underlying: Common Stock · 1,647 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 1,647 | $35.00 | $57,645.00 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 18:45 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 1,647 | $1.38 | $2,272.86 |
DisclosureSEC source: 0001593968-19-002318 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 19:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 1,250 | $17.00 | $21,250.00 |
DisclosureSEC source: 0001593968-19-002229 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,546 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 20,044 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001593968-19-002129 · primary_01.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,066 Underlying: Common Stock · 20,044 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 20,044 | $35.00 | $701,540.00 |
DisclosureSEC source: 0001593968-19-002129 · primary_01.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,296 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:34 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 20,044 | $1.38 | $27,660.72 |
DisclosureSEC source: 0001593968-19-002129 · primary_01.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 5, 2019. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | ConversionSeries C Preferred Stock · Derivative | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · derivative · entry 8 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | OtherSeries C Preferred Stock · Derivative | 501 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · derivative · entry 7 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,137 Underlying: Common Stock · 501 shares Expires not disclosed F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · kind: The Surace/Rogers Family Trust exercised a warrant to purchase 1,638 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. The Surace/Rogers Family Trust paid the exercise price on a cashless basis, resulting in the Issuer withholding 501 of the warrant shares to pay the exercise price and issued to The Surace/Rogers Family Trust the remaining 1,137 shares. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | OtherSeries C Preferred Stock · Derivative | 1,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · derivative · entry 6 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,638 Underlying: Common Stock · 1,638 shares Expires not disclosed F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · kind: The Surace/Rogers Family Trust exercised a warrant to purchase 1,638 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. The Surace/Rogers Family Trust paid the exercise price on a cashless basis, resulting in the Issuer withholding 501 of the warrant shares to pay the exercise price and issued to The Surace/Rogers Family Trust the remaining 1,137 shares. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | OtherSeries C Preferred Stock Warrant (Right to buy) · Derivative | 1,638 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · derivative · entry 5 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,638 shares Expires 2023-10-13 F3 · kind: The Surace/Rogers Family Trust exercised a warrant to purchase 1,638 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. The Surace/Rogers Family Trust paid the exercise price on a cashless basis, resulting in the Issuer withholding 501 of the warrant shares to pay the exercise price and issued to The Surace/Rogers Family Trust the remaining 1,137 shares. F4 · derivative.exercise_date: All of the shares subject to the warrant are fully exercisable as of the date hereof. F5 · ownership.nature: This warrant is held by the Surace/Rogers Family Trust. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | ConversionSeries C Preferred Stock · Derivative | 9,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · derivative · entry 4 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 9,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | ConversionCommon Stock | 1,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · nonDerivative · entry 2 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:02 UTC | Silk Road Medical Inc SILK · Entity 87417 | ConversionCommon Stock | 9,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-19-004134 · wf-form4_155493735281892.xml · nonDerivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 82,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust"). Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 21:32 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantEmployee Stock Option (Right to buy) · Derivative | 302,962 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001628280-19-003989 · wf-form4_155451434126651.xml · derivative · entry 1 Rogers Erica J. · CIK 0001769940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,962 Underlying: Common Stock · 302,962 shares Expires 2029-04-03 F1 · derivative.exercise_date: One forty-eighth of the shares subject to the option shall vest on May 3, 2019 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.